Risen MD

GLP Weight Loss · Compounded

Weight management with a dual-agonist option, reviewed by a licensed provider.

Compounded tirzepatide — a dual GLP-1 and GIP option — for patients a provider determines are candidates, with follow-up built in.

Three quick questions

Which form would you prefer?
Your provider confirms the form at review; the price shown follows your choice.
What term are you most interested in?
Have you used a service like this and for how long?

$196/mo$589 for 90 daysAs low as $187/mo · $1,119 for 180 daysShipping included. Prepaid multi-month pricing is locked at purchase.

Compounded medications are prepared by licensed U.S. compounding pharmacies for an individual patient under a prescription. They are not approved by the FDA and have not been evaluated by the FDA for safety, effectiveness, or quality.

Care is provided by independently licensed providers; eligibility isn't guaranteed and results vary.

You are only charged for medication if a licensed provider writes a prescription for you.

Start your consultationStart your consultation after answering the short questions above.

Intake and health information are handled by the licensed telehealth platform; this website never collects health information.

How it works

Four steps, every program.

The clinical review is never skipped, whatever you come here for.

  1. Intake.A private form inside a secure, HIPAA-compliant platform.
  2. Licensed-provider review.A licensed U.S. provider evaluates your intake and decides on treatment, which is never guaranteed.
  3. Shipment.The medication ordered is shipped discreetly to your home from a licensed 503A compounding pharmacy and typically arrives within 1–3 business days.
  4. Ongoing care.If prescribed, your care team follows up and adjusts the plan as needed.

Why tirzepatide

One molecule, two pathways — and a provider who decides which program fits.

Tirzepatide is a dual agonist: it acts on both the GLP-1 receptor and the GIP receptor, where semaglutide acts on the GLP-1 receptor alone. That is the whole of the difference this page states — it is a fact about the molecule, not a claim about results.

The compounded tirzepatide in this program is prepared by a licensed 503A compounding pharmacy for you individually and is not FDA-approved. The FDA-approved tirzepatide products carry their own labeling, which is the source for the safety statements on this page.

Which GLP-1 program is right for you is a clinical decision. A licensed provider reviews your history and may recommend semaglutide, tirzepatide, or neither. Choosing the higher-priced program is not a way to buy a stronger result — it is a different medication, prescribed when it is the appropriate one.

Evidence and sources

What the sources say.

Every clinical statement on this page carries its source and the date it was last reviewed.

Safety and candor

Not for everyone — and that is the point of the review.

Compounded medications are prepared by licensed U.S. compounding pharmacies for an individual patient under a prescription. They are not approved by the FDA and have not been evaluated by the FDA for safety, effectiveness, or quality. Compounded medications have not been evaluated by the FDA for safety or effectiveness.

Not for people with

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnancy, planning pregnancy, or breastfeeding
  • History of pancreatitis
  • History of severe gastrointestinal disease, including gastroparesis

Treatment, prescriptions, and eligibility are determined by a licensed provider following an evaluation, and are never guaranteed.

FAQ

Questions

What are reasons for not qualifying for GLP-1s?

A licensed provider decides after reviewing your intake. The following are common reasons for a provider to decline treatment or ask for further review:

  • BMI: An adult body mass index (BMI), calculated from the height and weight based upon your intake answers, which is below the range typically used for medical weight management. The range is typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or type 2 diabetes.
  • Medullary thyroid carcinoma or MEN 2: A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These medications should not be used in that case.
  • Pregnancy: These medications should not be used for weight loss during pregnancy. If you are planning a pregnancy or breastfeeding, your provider will review whether treatment is appropriate for you.
  • Pancreatitis: A history of pancreatitis is reviewed by your provider and may affect whether treatment is appropriate.
  • Severe gastrointestinal disease: These medications are not recommended for people with severe gastrointestinal disease, including severe gastroparesis.
  • Other conditions or medications: Other health conditions or medications your provider determines make treatment inappropriate.

The program must also be available in your state. Eligibility is never guaranteed, and you are only charged for medication if a prescription is written for you.

Is a prescription required?

Yes. A licensed provider reviews your intake first. You are only charged for medication if a prescription is written for you.

Which states is this available in?

See the availability page for the current list. The list is updated as coverage changes.

Clinical oversightLicensed U.S. providers review every intake. Treatment decisions are theirs, made after an evaluation.
Pharmacy networkLicensed U.S. compounding pharmacies, primary and backup, prepare compounded medications under a prescription.
Cash-pay clarityNot insurance. ID verification before treatment. One price per program and term, shown before you pay.
Private and discreetDiscreet packaging. Your care runs inside a secure portal, not over this website.